Quote | Nkarta Inc. (NASDAQ:NKTX)
Last: | $5.26 |
---|---|
Change Percent: | 1.2% |
Open: | $5.78 |
Close: | $5.26 |
High: | $5.89 |
Low: | $5.245 |
Volume: | 564,327 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Nkarta Inc. (NASDAQ:NKTX)
2024-07-01 10:20:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in...
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data ...
Message Board Posts | Nkarta Inc. (NASDAQ:NKTX)
Subject | By | Source | When |
---|---|---|---|
Turns out the trial in solid tumours (ccRCC, | jondoeuk | investorshub | 04/26/2023 2:17:08 AM |
(OT) Dr. Rezvani presented some early, but impressive | jondoeuk | investorshub | 04/25/2023 8:44:27 PM |
Updated results from the ongoing trial of NKX101 | jondoeuk | investorshub | 04/01/2023 8:35:01 PM |
ADAM17 knockout NK or CAR NK cells augment | jondoeuk | investorshub | 03/15/2023 2:00:46 AM |
Watching from the sidelines, but the NKX101 delayed | jondoeuk | investorshub | 02/13/2023 2:50:22 AM |
News, Short Squeeze, Breakout and More Instantly...
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data ...
2024-06-26 15:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...